| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/30/2004 | CA2518318A1 Histone deacetylase inhibitors |
| 09/30/2004 | CA2518227A1 Water-soluble phenylpyridazine derivative and medicine containing the same |
| 09/30/2004 | CA2517755A1 Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
| 09/30/2004 | CA2517671A1 Combinations of rapamycin or its derivatives and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases |
| 09/30/2004 | CA2517589A1 Method for preparing small particles |
| 09/30/2004 | CA2517588A1 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 09/30/2004 | CA2517191A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 09/30/2004 | CA2517186A1 Regulation of cell surface proteins |
| 09/30/2004 | CA2517125A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 09/30/2004 | CA2517034A1 Fused pyrrole compounds |
| 09/30/2004 | CA2515519A1 Medical use of ras antagonists for the treatment of capillary malformation |
| 09/30/2004 | CA2515195A1 Method and system for administering a drug |
| 09/30/2004 | CA2424053A1 Method of ameliorating side-effects of serms |
| 09/29/2004 | EP1462526A1 Novel tetronic acid derivative |
| 09/29/2004 | EP1462451A1 Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof |
| 09/29/2004 | EP1462450A1 Substituted morpholine derivatives and their use as therapeutic agents |
| 09/29/2004 | EP1462449A1 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 09/29/2004 | EP1462443A1 Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
| 09/29/2004 | EP1462439A1 Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same |
| 09/29/2004 | EP1462149A1 Medicament for the treatment of migraine based on phenazon |
| 09/29/2004 | EP1462148A2 Methods and compositions for the prevention of tolerance to bronchodilators |
| 09/29/2004 | EP1462125A2 Adhesive antineoplastic compositions |
| 09/29/2004 | EP1462117A1 Method for in vivo detection of antipsychotic properties of dopamine D3 receptor ligands |
| 09/29/2004 | EP1462114A1 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| 09/29/2004 | EP1462111A1 Composition for inducing immunotolerance |
| 09/29/2004 | EP1462108A1 Interferon g (g) production promoter |
| 09/29/2004 | EP1462107A1 Method of female contraception and kit for use in such method |
| 09/29/2004 | EP1462106A1 Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
| 09/29/2004 | EP1462105A1 Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases |
| 09/29/2004 | EP1462104A1 Optically pure (-) norcisapride for treating digestive tract disorders |
| 09/29/2004 | EP1462102A1 A method for promoting gonadal growth in an animal |
| 09/29/2004 | EP1462101A1 Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 09/29/2004 | EP1462100A1 Composition comprising formoterol and a glucosorticosteroid |
| 09/29/2004 | EP1462098A1 Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin |
| 09/29/2004 | EP1462097A1 Process for the preparation of enteric-coated and /or controlled-release medicaments containing active principles sensitive to gastrointestinal environment |
| 09/29/2004 | EP1462088A1 Composition for treating keratin fibers containing a hydroxycarboxylic acid and a protecting or conditionning agent |
| 09/29/2004 | EP1462081A1 Ceramide emulsions |
| 09/29/2004 | EP1462011A1 Comestibles containing Isomaltulose and Trehalose for sustained carbohydrate energy release and reduced glycemic/insulinimic responses |
| 09/29/2004 | EP1461457A2 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness |
| 09/29/2004 | EP1461450A1 T-bet compositions and methods of use thereof |
| 09/29/2004 | EP1461449A2 System for monitoring bacterial tumor treatment |
| 09/29/2004 | EP1461436A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 09/29/2004 | EP1461427A2 Methods for targeted expression of therapeutic nucleic acid |
| 09/29/2004 | EP1461424A2 Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding |
| 09/29/2004 | EP1461418A2 Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla) |
| 09/29/2004 | EP1461369A2 Block copolymers |
| 09/29/2004 | EP1461361A1 Negatively charged polysaccharide derivable from aloe vera |
| 09/29/2004 | EP1461359A2 Novel anti-igf-ir antibodies and uses thereof |
| 09/29/2004 | EP1461347A1 2-o-(-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 09/29/2004 | EP1461342A1 Streptogramin derivatives, preparation thereof and compositions containing same |
| 09/29/2004 | EP1461340A2 Trioxane derivatives as antimalaria or anticancer compounds |
| 09/29/2004 | EP1461339A2 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/29/2004 | EP1461337A1 Pyrido[2,1-a]isoquinoline derivatives as dpp-iv inhibitors |
| 09/29/2004 | EP1461336A2 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 09/29/2004 | EP1461334A2 Pyrazole derived kinase inhibitors |
| 09/29/2004 | EP1461333A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461327A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461326A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors |
| 09/29/2004 | EP1461325A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461323A2 Compounds for the treatment of metabolic disorders |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461319A1 Quinoline derivatives, synthesis method, and medicines containing said derivatives |
| 09/29/2004 | EP1461318A2 Tetrahydroquinoline analogues as muscarinic agonists |
| 09/29/2004 | EP1461316A2 Synthesis of 2-cyanoziridine-1-carboxamide |
| 09/29/2004 | EP1461313A1 Human adam-10 inhibitors |
| 09/29/2004 | EP1461311A2 Urea derivatives as vr1-antagonists |
| 09/29/2004 | EP1461306A1 Quaternary ammonium compounds and their use as antimuscarinic agents |
| 09/29/2004 | EP1461303A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE b-AMINO-ALCOHOLS |
| 09/29/2004 | EP1461165A1 Metallic structures incorporating bioactive materials and methods for creating the same |
| 09/29/2004 | EP1461122A2 Treatment of genitourinary tract disorders |
| 09/29/2004 | EP1461101A2 Metering valve and pharmaceutical metered dose inhaler and methods thereof |
| 09/29/2004 | EP1461090A2 Composition and method for treatment of otitis media |
| 09/29/2004 | EP1461084A2 Guanidinium transport reagents and conjugates |
| 09/29/2004 | EP1461083A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 09/29/2004 | EP1461076A2 Methods and compositions for treating lesions of the respiratory epithelium |
| 09/29/2004 | EP1461073A2 Peptide agonists of prostate-specific antigen, and uses therefor |
| 09/29/2004 | EP1461070A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 09/29/2004 | EP1461069A2 Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| 09/29/2004 | EP1461063A2 Treatment of glioblastoma with thymosin-alpha 1 |
| 09/29/2004 | EP1461062A2 Composition and method for treating chronic allograft rejection |
| 09/29/2004 | EP1461058A2 Supplements containing annatto extracts and carotenoids and methods for using the same |
| 09/29/2004 | EP1461056A2 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| 09/29/2004 | EP1461055A1 Anti-bacterial plant compositions |
| 09/29/2004 | EP1461051A1 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 09/29/2004 | EP1461050A1 Oral immunostimulation of mammals, birds, and reptiles from (1-4) linked beta-d-mannuronic acid |
| 09/29/2004 | EP1461049A1 Use of sulfated glycosaminoglycans for establishing effective labor in women |
| 09/29/2004 | EP1461048A1 Buffalo milk gangliosides |
| 09/29/2004 | EP1461047A1 Compositions and methods for animal treatment |
| 09/29/2004 | EP1461046A2 Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells |
| 09/29/2004 | EP1461045A2 Glucosamine organic acid adducts |
| 09/29/2004 | EP1461044A1 Pharmaceutical compositions comprising active vitamin d compounds |
| 09/29/2004 | EP1461043A1 Oral pharmaceutical products containing 17 beta-estradiol-3 lower alkanoate, method of administering the same and process of preparation |
| 09/29/2004 | EP1461042A1 Use of desoxypeganine for treating clinical depression |
| 09/29/2004 | EP1461040A1 Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| 09/29/2004 | EP1461039A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 09/29/2004 | EP1461038A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 09/29/2004 | EP1461037A2 Beverage treated with nicotine |
| 09/29/2004 | EP1461036A2 Bis hydrochloride monohydrate salt of rsv fusion inhibitor |
| 09/29/2004 | EP1461034A1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
| 09/29/2004 | EP1461033A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy |